For the year ending 2025-12-31, TMCI had -$642K decrease in cash & cash equivalents over the period. -$29,487K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -59,002 |
| Depreciation and amortization expense | 10,623 |
| Provision for allowance for credit losses | 834 |
| Share-based compensation expense | 33,823 |
| Non-cash lease expense | 2,222 |
| Amortization of debt issuance costs | 292 |
| Debt extinguishment loss | 2,737 |
| Amortization (accretion) of premium (discount) on marketable securities, net | 123 |
| Other, net | -1,208 |
| Accounts receivable | 2,090 |
| Inventory | -3,224 |
| Prepaid expenses and other assets | -166 |
| Other non-current assets | 503 |
| Operating lease liabilities | -3,207 |
| Accounts payable | -3,796 |
| Accrued liabilities | -2,413 |
| Other, net | -35 |
| Net cash provided by (used in) operating activities | -15,970 |
| Purchases of available-for-sale marketable securities | 40,571 |
| Sales and maturities of available-for-sale marketable securities | 67,339 |
| Purchases of property and equipment | 13,517 |
| Acquisition, net of cash acquired | 0 |
| Net cash provided by (used in) investing activities | 13,251 |
| Proceeds from interest bearing term debt | 59,310 |
| Proceeds from insurance premium financing | 1,553 |
| Debt issuance costs | 1,199 |
| Payments on interest bearing term and revolving debt | 56,315 |
| Payments on insurance premium financing | 916 |
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of 7.5 million | 0 |
| Proceeds from exercise of employee stock options | 546 |
| Taxes from withheld shares | 902 |
| Net cash provided by (used in) financing activities | 2,077 |
| Net increase (decrease) in cash and cash equivalents | -642 |
| Cash and cash equivalents at beginning of period | 11,350 |
| Cash and cash equivalents at end of period | 10,708 |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)